AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32969717 — intervention group
Group type: EXPERIMENTAL
Intervention: SELE protein level
Number of subjects: 0
Study 32969717 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation site cg05126514 within the BSN gene
Number of subjects: 0
Study 32969717 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptional regulatory genes (SF3A3, ILF3, N4BP2L2)
Number of subjects: 0
Study 34965188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention combined with standard care (N = 64)
Number of subjects: 98
Study 34965188 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (N = 34)
Number of subjects: 98
Study 34965188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 98
Study 34965188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention and/or pharmacological interventions
Number of subjects: 98
Study 33678124 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look resection (SLR) performed in 642 (26%) individuals
Number of subjects: 2456
Study 33678124 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look resection (SLR)
Number of subjects: 2456
Study 32119096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Number of subjects: 94
Study 32119096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 34284374 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS) - 1 single placement
Number of subjects: 323
Study 35466448 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg sc monthly
Number of subjects: 11224
Study 35466448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11224
Study 35466448 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg po weekly
Number of subjects: 11224
Study 35466448 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 11224
Study 33485453 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib plus gemcitabine
Number of subjects: 124
Study 33485453 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 124
Study 34736818 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 50
Study 34736818 — intervention group
Group type: COMPARATOR
Intervention: Sham taping
Number of subjects: 50
Study 33838307 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model of long-acting injectable buprenorphine (ID/LAB)
Number of subjects: 200
Study 33838307 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study 32719239 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal endoscopic sphincterotomy followed by papillary balloon dilation (ESBD)
Number of subjects: 435
Study 32719239 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 435
Study 34431612 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture (ISSA) at parietal midline [MS5], left anterior parietotemporal oblique line [MS6], left posterior parietotemporal oblique line [MS7] for one course of treatment.
Number of subjects: 30
Study 34431612 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine (control group).
Number of subjects: 30
Study 34290695 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants on ART
Number of subjects: 289
Study 34290695 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 289
Study 34290695 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL1 immune marker
Number of subjects: 289
Study 34290695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation patterns
Number of subjects: 289
Study 34290695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine immune markers identified by ANCOVA
Number of subjects: 289
Study 33126336 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 0
Study 33126336 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 0
Study 35180726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast-saw alarm
Number of subjects: 31
Study 33158633 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional corticotomy
Number of subjects: 40
Study 33158633 — intervention group
Group type: COMPARATOR
Intervention: Flapless corticotomy
Number of subjects: 40
Study 34311441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) training for 4 weeks, 3 times per week
Number of subjects: 19
Study 34311441 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no intervention for 4 weeks
Number of subjects: 19
Study 34218211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) at a median modal dose of 150 mg/day for a median treatment duration of 2.5 years.
Number of subjects: 284
Study 34218211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment for ≥ 1 year.
Number of subjects: 284
Study 34218211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment after 1 and 2 years.
Number of subjects: 284
Study 34218211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment.
Number of subjects: 284
Study 36211683 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertisements
Number of subjects: 200
Study 35184471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting poor ovarian response (POR) based on factors such as age, infertility type, body mass index, anti-Müllerian hormone, basal follicle stimulating hormone, basal estrogen, antral follicle number, previous times of POR, history of ovarian surgery, ovulation stimulation protocol, average amount of gonadotropin.
Number of subjects: 13266
Study 33231679 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Me, Healthy We intervention (8-month social marketing intervention)
Number of subjects: 853
Study 33231679 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 853
Study 32912298 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 140
Study 32912298 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment
Number of subjects: 140
Study 36038128 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted colonoscopy
Number of subjects: 5796
Study 36038128 — intervention group
Group type: COMPARATOR
Intervention: Non-AI colonoscopy
Number of subjects: 5796
Study 34653608 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D3 (25(OH)D3)
Number of subjects: 106
Study 34653608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 32761987 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook training (Phase 1 and Phase 2)
Number of subjects: 341
Study 32761987 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook training (Phase 1)
Number of subjects: 341
Study 32761987 — intervention group
Group type: COMPARATOR
Intervention: Control group (Phase 1 and Phase 2)
Number of subjects: 341
Study 35498888 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids combined with renin‐angiotensin system blockers (RASBs)
Number of subjects: 426
Study 35498888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin combined with RASBs
Number of subjects: 426
Study 35498888 — intervention group
Group type: COMPARATOR
Intervention: RASBs alone
Number of subjects: 426
Study 33590955 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg Aged Garlic Extract (AGE) daily for 1 year
Number of subjects: 93
Study 33590955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 33279636 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined walking along a 5‐m walkway of three different path widths (15, 25, and 50 cm)
Number of subjects: 20
Study 33279636 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined walking along the aforementioned paths while PFC activity was measured using functional near‐infrared spectroscopy
Number of subjects: 20
Study 33279636 — intervention group
Group type: COMPARATOR
Intervention: Comparison with young adults from a previous study
Number of subjects: 20
Study 34990291 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of concurrent 100 mg/m2 DDP
Number of subjects: 332
Study 34990291 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of concurrent DDP
Number of subjects: 332
Study 33797427 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo‐Medrol (40 mg/1 cc)
Number of subjects: 73
Study 33797427 — intervention group
Group type: COMPARATOR
Intervention: Control (saline 1 cc)
Number of subjects: 73
Study 32571395 — intervention group
Group type: EXPERIMENTAL
Intervention: Miao crossbow needle therapy (CN)
Number of subjects: 301
Study 32571395 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (AT)
Number of subjects: 301
Study 35221215 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway (ICP)
Number of subjects: 145
Study 35221215 — intervention group
Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 145
Study 34365776 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 264
Study 32780643 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab/erlotinib
Number of subjects: 0
Study 32780643 — intervention group
Group type: COMPARATOR
Intervention: placebo/erlotinib
Number of subjects: 0
Study 36152018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral function intervention (one-on-one lesson on oral exercise and preventive oral care)
Number of subjects: 114
Study 33710023 — intervention group
Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir disoproxil fumarate preexposure prophylaxis (FTC/TDF PrEP)
Number of subjects: 0
Study 33710023 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 32404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Care Model (CCM)
Number of subjects: 60
Study 32404725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 35570712 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-allergoids 3000 mTU SC
Number of subjects: 196
Study 35570712 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-allergoids 5000 mTU SC
Number of subjects: 196
Study 35570712 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-allergoids 3000 mTU SL
Number of subjects: 196
Study 35570712 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-allergoids 5000 mTU SL
Number of subjects: 196
Study 35570712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 33025730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 2.6 mg/m2 (MTD) given orally once daily for 21 consecutive days of a 28-day cycle
Number of subjects: 29
Study 33025730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 3.4 mg/m2 (dose level 3)
Number of subjects: 29
Study 33025730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Number of subjects: 29
Study 33175164 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-temperature plasma radiofrequency ablation (LTP-RFA)
Number of subjects: 204
Study 33175164 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency thermocoagulation (RFT)
Number of subjects: 204
Study 32693653 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream (5% lidocaine‐prilocaine cream)
Number of subjects: 100
Study 32693653 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study 33612377 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized insole
Number of subjects: 23
Study 33612377 — intervention group
Group type: COMPARATOR
Intervention: Toe separator
Number of subjects: 23
Study 33459175 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 20
Study 33459175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33753956 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 60
Study 33753956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32984918 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 32984918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 0
Study 32984918 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic surgery (general)
Number of subjects: 0
Study 32009473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-immuno-therapy (combination of cryotherapy with intralesional Candida antigen)
Number of subjects: 60
Study 32009473 — intervention group
Group type: COMPARATOR
Intervention: Intralesional Candida antigen monotherapy
Number of subjects: 60
Study 32009473 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 60
Study 35666133 — intervention group
Group type: EXPERIMENTAL
Intervention: MITP group (n=30)
Number of subjects: 60
Study 35666133 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study 33177808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 5mg
Number of subjects: 150
Study 33177808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5μg
Number of subjects: 150
Study 33177808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dezocine and sufentanil (1:3, 1:1, 3:1)
Number of subjects: 150
Study 35125219 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS-1 adjuvanted IIV (1, 3, 5, or 9 µg per HA)
Number of subjects: 72
Study 35125219 — intervention group
Group type: COMPARATOR
Intervention: Standard dose IIV (Fluzone SD, 15 µg per HA)
Number of subjects: 72
Study 34473350 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 0
Study 34473350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remote ischaemic conditioning)
Number of subjects: 0
Study 33762179 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle-medical treatment to targets and PET guided interventions
Number of subjects: 1028
Study 33762179 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Standard group)
Number of subjects: 1028
Study 32241789 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Number of subjects: 30
Study 32241789 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Number of subjects: 30
Study 32241789 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture treatment
Number of subjects: 30
Study 32241789 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 30
Study 35982492 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) game during dressing changes
Number of subjects: 35
Study 35982492 — intervention group
Group type: COMPARATOR
Intervention: Standard distraction techniques available in the home
Number of subjects: 35
Study 33103379 — intervention group
Group type: COMPARATOR
Intervention: HBex (blended home-based exercise intervention)
Number of subjects: 245
Study 33103379 — intervention group
Group type: COMPARATOR
Intervention: HBex-Pro (blended home-based exercise with dietary protein counselling)
Number of subjects: 245
Study 33103379 — intervention group
Group type: COMPARATOR
Intervention: HBex-Pro
Number of subjects: 245
Study 33103379 — intervention group
Group type: COMPARATOR
Intervention: HBex, HBex-Pro
Number of subjects: 245
Study 33992238 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral dry needling (PDN)
Number of subjects: 34
Study 33992238 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal and peripheral dry needling (SPDN)
Number of subjects: 34
Study 36417043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous bone chips from iliac crest (Group A)
Number of subjects: 72
Study 36417043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical bone chips harvested from maxilla using a curved bone scraper, covered with PRF (Group B)
Number of subjects: 72
Study 33124098 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 24
Study 33124098 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision (Piezo)
Number of subjects: 24
Study 33124098 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 24
Study 35351158 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality navigation system
Number of subjects: 22
Study 35351158 — intervention group
Group type: COMPARATOR
Intervention: Traditional optical navigation
Number of subjects: 22
Study 34825770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroid with QR678 Neo®
Number of subjects: 20
Study 34825770 — intervention group
Group type: COMPARATOR
Intervention: Intralesional steroid alone
Number of subjects: 20
Study 32571718 — intervention group
Group type: EXPERIMENTAL
Intervention: Agriflu®
Number of subjects: 183
Study 32571718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluzone®
Number of subjects: 183
Study 32571718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix®
Number of subjects: 183
Study 32571718 — intervention group
Group type: COMPARATOR
Intervention: Control (non-pregnant women)
Number of subjects: 183
Study 32571718 — intervention group
Group type: EXPERIMENTAL
Intervention: All IIV3s
Number of subjects: 183
Study 34344416 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher soluble thrombomodulin (sTM) levels
Number of subjects: 432
Study 34344416 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial and slope of sTM levels
Number of subjects: 432
Study 32390540 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical education curriculum
Number of subjects: 12
Study 32390540 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of experience
Number of subjects: 12
Study 35940251 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (100 mg oral, twice daily for 8 weeks)
Number of subjects: 166
Study 35940251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 8 weeks)
Number of subjects: 166
Study 35940251 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 166
Study 35940251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 33602684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 326
Study 33602684 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 326
Study 32701419 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + TES (n=48, analyzed = 41)
Number of subjects: 95
Study 32701419 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU, n=47)
Number of subjects: 95
Study 36227604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluorouracil/leucovorin (MOSAIC trial)
Number of subjects: 3186
Study 36227604 — intervention group
Group type: COMPARATOR
Intervention: Modified FOLFOX-6 regimen (US Oncology)
Number of subjects: 3186
Study 34153143 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (anti-IL-6 antibody)
Number of subjects: 20
Study 34153143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32239786 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube (ETT) insertion depth based on birth weight
Number of subjects: 40
Study 32239786 — intervention group
Group type: COMPARATOR
Intervention: Gestational age for estimating ETT insertion depth
Number of subjects: 40
Study 34238555 — intervention group
Group type: EXPERIMENTAL
Intervention: Firesorb BRS
Number of subjects: 433
Study 34238555 — intervention group
Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 433
Study 35195306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 50 mg Zoledronic acid (ZA) once-a-week for 6 weeks
Number of subjects: 25
Study 35195306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 34420816 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg a day
Number of subjects: 24
Study 34420816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32277937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 71
Study 32277937 — intervention group
Group type: COMPARATOR
Intervention: Panoramic radiography (OPG)
Number of subjects: 71
Study 32277937 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 71
Study 32277937 — intervention group
Group type: COMPARATOR
Intervention: OPG
Number of subjects: 71
Study 35525971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 238
Study 32465404 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free, everolimus (EVR)-based immunosuppression
Number of subjects: 12
Study 36282834 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor Ailment Service (MAS)
Number of subjects: 808
Study 36282834 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 808
Study 32453274 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support intervention
Number of subjects: 30
Study 32453274 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 36287389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg 1% lidocaine (0.15 ml/kg)
Number of subjects: 60
Study 36287389 — intervention group
Group type: COMPARATOR
Intervention: 0.15 ml/kg 0.9% NaCl (placebo)
Number of subjects: 60
Study 32660264 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 40
Study 35596730 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-cookie (10 g grapeseed oil per day)
Number of subjects: 84
Study 35596730 — intervention group
Group type: COMPARATOR
Intervention: OA-cookie (10 g high oleate safflower oil per day)
Number of subjects: 84
Study 34310352 — intervention group
Group type: EXPERIMENTAL
Intervention: Swabs containing tea tree oil and chamomile oil
Number of subjects: 49
Study 34310352 — intervention group
Group type: COMPARATOR
Intervention: Baby Shampoo (BS)
Number of subjects: 49